The Osteoarthritis Market Size was valued at USD 4.3 billion in 2022 and is projected to grow from USD 4.69 Billion in 2023 to USD 10.27 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.1% during the forecast period (2023 - 2032). The growing awareness about the disease and the availability of advanced treatment options drive the market growth for osteoarthritis treatment. The increasing demand for minimally invasive and non-surgical treatments, such as physical therapy, drugs, and injections, also contributes to the market growth of the osteoarthritis. These are just a few of the market drivers that are driving the market.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Robexera, the first generic robenacoxib medication, will be available in 2023, according to Krka. It is intended to treat pain and inflammation brought on by soft tissue surgery and persistent osteoarthritis (OA) in dogs. A once-daily dosage schedule for Robexera, a COX2 NSAID formulation, provides anti-inflammatory pain relief2,3,4. The medicine comes in the form of a chewable tablet with flavoring to make it easier for pet owners to administer. It comes in four strengths for ease of administering, and each pack includes a set of PIL sheets that can be converted into prescription envelopes, color-coded boxes, and perforated blisters.
The U.S. Food and Drug Administration (U.S. FDA) has granted Zydus Lifesciences final permission in 2023 to produce and distribute 50 mg/200 mcg and 75 mg/200 mcg of Misoprostol Delayed Release Tablets USP, as well as 0.5 mg and 1 mg of Varenicline tablets. Arthrotec Delayed-Release tablets are the reference listed drug (RLD) for Diclofenac Sodium and Misoprostol Delayed Release Tablets. These tablets are intended to treat rheumatoid arthritis and osteoarthritis in individuals who are at high risk of developing stomach or intestinal ulcers. According to Zydus, the medication would be produced at the group's Ahmedabad formulation manufacturing facility. The product's annual sales in the United States were $13 million, according to the business, which cited IQVIA MAT March 2023 numbers.
The geriatric population and the growing incidence of osteoarthritis also contribute to the market's growth. The increasing awareness about the benefits of non-invasive pain management options and the availability of technologically advanced products are expected to drive osteoarthritis market growth further. The market is expected to grow with the development of novel and more effective pain management products and treatments and with increasing research and development investments by companies. Thus, this factor is driving the market CAGR.
Personalized medicine can help to better manage OA by tailoring treatment plans based on an individual's unique characteristics and underlying biology, thus optimizing the benefits of therapy and minimizing any adverse effects. The use of biomarkers for diagnosis and prognosis in OA, along with advancements in technology and the development of new drugs, is expected to drive the growth of the personalized medicine market for osteoarthritis treatment.
In addition, the development of targeted therapies, such as small molecule inhibitors and biologics, is expected to drive the market growth of osteoarthritis. The increasing need for non-invasive and minimally invasive surgical procedures, and the use of regenerative therapies, such as stem cell and platelet-rich plasma therapy, is anticipated to drive the market growth of osteoarthritis. The sedentary lifestyle are also contributing to the market growth. Thus, it is anticipated that this aspect will accelerate market revenue of Osteoarthritis.
The market for osteoarthritis segmented, based on type, includes hip osteoarthritis, spinal osteoarthritis. The arabica segment held the majority share in 2022 in the market of Osteoarthritis data. The increasing adoption of sedentary lifestyles, coupled with increasing obesity rates, is also driving the spinal osteoarthritis market growth. The growing market for minimally invasive surgical procedures and the development of new treatments are also boosting the market growth.
The Osteoarthritis market segmentation, based on diagnosis, includes imaging and joint fluid analysis. The imaging segment dominated the market growth osteoarthritis in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Imaging technologies play a crucial role in the diagnosis and management of osteoarthritis. Radiography is the most commonly used imaging modality in osteoarthritis research and clinical management, while MRI and ultrasound are used in atypical cases or when the rapid progression of symptoms is observed.
Figure 2: Osteoarthritis Market, by Diagnosis, 2022 & 2030 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The market data of Osteoarthritis, based on treatment, includes medication, surgery, and therapy. The medication segment dominated the osteoarthritis market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This is due to the rise in the adoption of nonsteroidal anti-inflammatory drugs (NSAIDs), the increase in the number of new product launches, and the increase in the number of prescriptions. Due to the increase in the prevalence of osteoarthritis, advancements in R&D for developing new viscosupplementation agents, and government initiatives to support research in the healthcare sector.
The market segment of Osteoarthritis, based on end-user, includes hospital, and medical institutes. The hospital segment dominated the market revenue of osteoarthritis in 2022 and is projected to be the faster-growing segment during the forecast period. The hospital segment was the major contributor in 2022 and is expected to maintain its lead due to government initiatives and the rise in the prevalence of osteoarthritis.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Osteoarthritis market accounted for USD 1.96 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. Additionally, the rising awareness of osteoarthritis and increasing investment in research and development activities by pharmaceutical companies are contributing to the market growth of osteoarthritis in North America. The high adoption of advanced medical technologies and the existence of major regional players are expected to boost market growth. New product development, partnerships, partnerships, expansions, mergers, and acquisitions are the main strategies used by the organisations in the market.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: OSTEOARTHRITIS MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Osteoarthritis market accounts for the second-largest market share. Europe is expected to continue to rapidly grow the market for osteoarthritis due to the factors mentioned, such as the high prevalence of knee osteoarthritis, increase in the number of drug approvals, presence of key players in the market, availability of advanced research activities for drug development, and increase in the number of clinical studies to evaluate the safety and efficacy of drugs. Moreover, UK market of Osteoarthritis held the largest market share, and the Germany market of Osteoarthritis was the fastest growing market in the region.
Asia Pacific Osteoarthritis Market is expected to grow at the fastest CAGR from 2022 to 2030. The Asia-Pacific market is expected to witness considerable development during the forecast period due to a large patient pool, an increasing geriatric population, and healthcare spending. The rise in the number of osteoarthritis patients and the growing demand for advanced osteoarthritis treatments are also anticipated to propel the market growth in the region. In addition, increasing initiatives taken by the government to develop the healthcare sector, and growing number of clinical trials and studies conducted in the region are some of the factors expected to contribute to the growth of the Asia-Pacific market of Osteoarthritis. Further, the China market of Osteoarthritis held the largest market share, and the India market of Osteoarthritis was the fastest growing market in the region.
Osteoarthritis Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Competitors in the osteoarthritis industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the osteoarthritis industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, osteoarthritis industry has provided medicine with some of the most significant benefits. The osteoarthritis market major player such as Abbott, Novartis AG, Pfizer Inc., Eli Lilly and Company., ABIOGEN PHARMA S.p.A, Merck Sharp & Dohme Corp.
GSK is a leading player in the pharmaceutical industry, specializing in developing and manufacturing innovative medicines, vaccines, and consumer healthcare products. The company operates ly and has a presence in over 150 countries. GSK has a strong portfolio of prescription drugs and consumer healthcare products, including treatments for respiratory diseases, HIV, cancer, and vaccines. It also has a significant research and development program, focusing on developing new treatments for unmet medical needs. In 2020, GSK launched its new offering Voltaren in the US.
Flexion Therapeutics is focused on developing and commercializing local therapies for musculoskeletal conditions, particularly osteoarthritis, a common form of arthritis. The company is based in Burlington, Massachusetts, USA. In 2017, Flexion Therapeutics got approval from the FDA for their new offering in the US ZILRETTA.
Key Companies in the market of Osteoarthritis includes
Osteoarthritis Industry Developments
Robexera, the first generic robenacoxib medication, will be available in 2023, according to Krka. It is intended to treat pain and inflammation brought on by soft tissue surgery and persistent osteoarthritis (OA) in dogs. A once-daily dosage schedule for Robexera, a COX2 NSAID formulation, provides anti-inflammatory pain relief2,3,4. The medicine comes in the form of a chewable tablet with flavoring to make it easier for pet owners to administer. It comes in four strengths for ease of administering, and each pack includes a set of PIL sheets that can be converted into prescription envelopes, color-coded boxes, and perforated blisters.
The U.S. Food and Drug Administration (U.S. FDA) has granted Zydus Lifesciences final permission in 2023 to produce and distribute 50 mg/200 mcg and 75 mg/200 mcg of Misoprostol Delayed Release Tablets USP, as well as 0.5 mg and 1 mg of Varenicline tablets. Arthrotec Delayed-Release tablets are the reference listed drug (RLD) for Diclofenac Sodium and Misoprostol Delayed Release Tablets. These tablets are intended to treat rheumatoid arthritis and osteoarthritis in individuals who are at high risk of developing stomach or intestinal ulcers. According to Zydus, the medication would be produced at the group's Ahmedabad formulation manufacturing facility. The product's annual sales in the United States were $13 million, according to the business, which cited IQVIA MAT March 2023 numbers.
September 2022: StemOne, the off-the-shelf cell therapy product by Alkem Laboratories, received regulatory approval from the Drug Controller General of India (DCGI) for its launch in India. This product is being launched in collaboration with Stempeutics, which aims to treat knee osteoarthritis, a degenerative joint disease.
August 2022: Shionogi & Co., Ltd. and Grünenthal GmbH have entered into a licensing agreement to jointly market and commercialize injectable resiniferatoxin in Japan. Resiniferatoxin is a pipeline product developed by Grünenthal, and it is intended to treat pain caused by osteoarthritis of the knee. The licensing agreement will allow the companies to bring the product to market in Japan, offering a new treatment option for patients with knee osteoarthritis.
North America
Europe
Asia-Pacific
Rest of the World
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 4.3 billion |
| Market Size 2023 | USD 4.69 billion |
| Market Size 2032 | USD 10.27 billion |
| Compound Annual Growth Rate (CAGR) | Â 9.1% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Diagnosis, Treatment, End-User and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Abbott, Novartis AG, Pfizer Inc., Eli Lilly and Company., ABIOGEN PHARMA S.p.A, Merck Sharp & Dohme Corp. |
| Key Market Opportunities | Asia-pacific countries |
| Key Market Dynamics | Growing aging population ly |
Osteoarthritis Market Highlights:
Frequently Asked Questions (FAQ) :
The Osteoarthritis market size was valued at USD 4.3 Billion in 2022.
The market is projected to grow at a CAGR of 9.1% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are Abbott, Novartis AG, Pfizer Inc., Eli Lilly and Company., ABIOGEN PHARMA S.p.A, Merck Sharp & Dohme Corp.
The key players in the market are Abbott, Novartis AG, Pfizer Inc., Eli Lilly and Company., ABIOGEN PHARMA S.p.A, Merck Sharp & Dohme Corp.
The spinal osteoarthritis category dominated the market in 2022.
The hospitals had the largest share in the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
